相关实验视频
Updated: Jun 9, 2026

Mouse Models of Periventricular Leukomalacia
Published on: May 18, 2010
在S1P-RM和纳塔利祖马布相关的渐进多焦点白血脑病的表现和结果:一个多中心队列研究
Julie C Blant1, Nicola N De Rossi1, Ralf Gold1
1From the Service of Neurology (J.C.B., R.A.D.P., R.B.-V.), Department of Clinical Neurosciences, Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois) and University of Lausanne, Switzerland; Regional Multiple Sclerosis Center (N.N.D.R.), ASST-Spedali Civili di Brescia, Montichiari, Italy; Department of Neurology St. Josef-Hospital (R.G., I.A.), Ruhr University Bochum, Germany; Centre Hospitalier Régional Universitaire de Tours (A.M.), Hôpital Bretonneau, Service de neurologie, Tours, France; Department of Neurology (M.K.), Alfried Krupp von Bohlen und Halbach Hospital, Essen; Department of Neurology (M.K.), Medical Faculty, Heinrich Heine University of Düsseldorf, Germany; Neurology Department (L.R.-P.), Multiple Sclerosis Unit, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain; Department of Neurology (T.M.), Tohoku University Hospital, Japan; Service de Neurologie (J.-C.O.), Pôle des Neurosciences Cliniques, CHU de Bordeaux Pellegrin Tripode; Service de Neurologie et Unité Neurovasculaire (M.P.G.), Centre Hospitalier Régional d'Orléans, France; Unit of Neuroradiology (S.G.), Papa Giovanni XXIII Hospital, Bergamo, Italy; Multiple Sclerosis Center (C.B.), Second Department of Neurology, Aristotle University of Thessaloniki, Greece; Servicio de Neurología (R.P.M.), Hospital Universitario Clínico San Cecilio, Granada, Spain; Department of Neurology (B.V., I.J.), University Hospital Zurich and University of Zurich, ; Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience (P.K., T.J.D.), Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, Switzerland; Service de Neurologie (X.M.), Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol; Infectious and Tropical Diseases Unit (G.M.-B.), University Hospital of Toulouse, France; Department of Neurology (C.M.), State University of New York Upstate Medical University, Syracuse; and CHU Nantes (D.A.L.), Service de Neurologie, CRC-SEP, Nantes Université, INSERM, CIC 1413, Center for Research in Transplantation and Translational Immunology, UMR 1064, France.
氨酸-1-酸受体调节剂 (S1P-RMs) 和纳塔利祖马布治疗多发性硬化症 (MS) 携带进展性多焦点白内障 (PML) 的风险. 与S1P-RM相关的PML呈现不同,具有较低的IRIS风险,但在治疗后增加了MS活动.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 渐进性多焦点白内障 (PML) 是一种严重的机会性感染,由免疫功能低下个体的JC病毒重新激活引起.
- 某些多发性硬化症 (MS) 疾病修饰疗法 (DMT),包括纳塔利祖马布和斯芬戈-1-酸盐受体调节剂 (S1P-RMs),与PML的风险增加有关.
- 虽然纳塔利祖马布相关的PML的特征很好,但对S1P-RM相关的PML的数据仍然有限.
研究的目的:
- 为了比较S1P-RMs治疗患者与纳塔利祖马布治疗的PML的临床表现和结果.
- 为了确定两组治疗群体之间的疾病特征,免疫复合炎症综合征 (IRIS) 发展和PML后疾病活动的差异.
主要方法:
- 一项回顾性多中心队列研究包括了在2009年至2022年期间被诊断患有PML的患者.
- 患者根据先前的S1P-RMs或natalizumab治疗情况进行了分层.
- 分析的数据包括临床和放射性表现,IRIS,存活率,残疾 (修改的兰金尺度 - mRS) 和PML后MS复发.
主要成果:
- 在分析的84名患者中,有20人接受S1P-RMs,64人接受纳塔利祖马布.
- 与S1P-RM相关的PML发生在老年患者中,治疗持续时间较长,并且呈现出更广泛的病变和更高的加多增强.
- 纳塔利祖马布治疗的患者患上IRIS的发病率较高,而S1P-RM患者在治疗后表现出显著更高的MS活动.
结论:
- 与S1P-RMs相关的PML在呈现和IRIS风险方面与纳塔利祖马布相关的PML不同.
- 在S1P-RM组中治疗后MS活动的增加需要谨慎的管理策略.
- 在PML后的治疗决定中,应考虑患者之前的DMT,以指导量身定制的治疗方法.
更多相关视频
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
相关概念视频
Encephalitis ll: Pathophysiology
Multiple Sclerosis l: Introduction